Dr. Haley is Alumni Professor of Neurology and Neurological Surgery at the University of Virginia School of Medicine in Charlottesville, VA. Dr. Haley will be the Principal Investigator for the NeuroNEXT clinical site at the University of Virginia. He has been engaged in clinical trial work in acute stroke and subarachnoid hemorrhage for over 25 years. He helped to pilot the development of recombinant tissue plasminogen activator beginning in 1986 and was a member of the Steering Committee for the NINDS TPA Stroke Trial. He was the Co-Principal Investigator of the Coordinating Center for the Randomized Trial of Nicardipine in Subarachnoid Hemorrhage and both the North American and European/Australian Trials of Tirilazad in Subarachnoid Hemorrhage. He was also the Principal Investigator of the Coordinating Center of the Phase II and III trials of Tirilazad in Acute Ischemic Stroke, as well as the North American Phase II studies of gavestinel in acute ischemic stroke (GAIN). More recently, he was the Principal Investigator for the early dose escalation and middle phase studies of tenecteplase (TNK) in acute ischemic stroke. He is the author of numerous publications in cerebrovascular disease.

Clinical Sites

University of Virginia – Charlottesville

E. Clarke Haley, Jr., M.D., Principal Investigator